April 12, 2022 | Lucid Group, Medical Communications, Pharma, healthcare communications, launch

In the April edition of PME, Cheryl Harrison Doyle, Global Asset Strategy Director at Lucid Group discusses the need to take a more considered, outcomes-led approach when launching new medicines today.
With a rapidly changing clinical, economic and regulatory environment, the launch of new products has catapulted the pharmaceutical industry into greater complexity and pressure than ever before. Historically, new asset launches have been a tale of two halves: a hit or miss. Between 2009 and 2017, 40% of worldwide drug launches failed to meet their 2-year sales forecasts, according to McKinsey & Company1. Taking into consideration the evolving environment, there has never been a greater need for new models to navigate the path of an asset to market.
Over the past 15 years, our clients have regularly come to us to help them execute their launch plans. Often the ask is around launch readiness and activation, with a focus on tactical execution. In this article, we discuss the need to get ahead of tactical planning and demonstrate the role of ‘pre-launch asset preparedness’, to ensure we maximise the potential of specialised medicines in this highly complex environment.
You can read the full article online here or download it so you can read it later here.
If you’re planning a launch and looking for some advice, get in touch! We’re hosting free launch-strategy clinics throughout May and June. Contact Cheryl Harrison Doyle or Clare Reynolds for more details.
This content was provided by Lucid Group Communications Limited
Company Details
Latest Content from Lucid Group Communications Limited
Rick Sannem, outgoing CEO, transitions to Strategic Advisor to the Board
Appointment marks a pivotal step in Lucid’s next phase of growth, strengthening its ability to translate complex science into real-world impact. Lucid’s US Medical Affairs division unveils new proprietary insights…
Lucid Group announces the evolution of its consulting division, Lucid Strategy Consulting, setting a new standard for deep-domain, knowledge-led consulting solutions for life sciences. We have brought together two Lucid…
Working in Medical Communications has never been about the nine to five. Fusing science and language in the service of both clients and patients, this is typically a fast paced…
In April’s PME, Danny Buckland has been talking to industry leaders about launch excellence in the featured article, Listen, learn and lift off.Buckland points out that pandemic storms have changed the…
In the April edition of PME, Cheryl Harrison Doyle, Global Asset Strategy Director at Lucid Group discusses the need to take a more considered, outcomes-led approach when launching new medicines…
Meet our talent team, they’re here to help and transform your career.We have some exciting roles at all levels in account management and medical writing.If you choose to take your…
In support of Rare Disease Day, we’re excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so…
In support of Rare Disease Day, we’re excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so…
